1.This Act may be cited as
the Influenza Vaccine Security Act of
2007
.
<enum>I</enum><header>Market
Guarantees</header>
<section id="id57FBBF3EFBBC40A38BAF317097E037A8"><enum>101.</enum><header>Amendment to
the Public Health Service Act</header><text display-inline="no-display-inline">Title XXI of the Public Health Service Act
(42 U.S.C. 300aa–1 et seq.) is amended by adding at the end the
following:</text>
<quoted-block display-inline="no-display-inline" id="idF263A06D4E814444AF0BBE88C8206631" style="OLC">
<subtitle id="idA9D0459A4370490283AEE3D65D87CCBF"><enum>3</enum><header>Influenza vaccine
security</header>
<section commented="no" display-inline="no-display-inline" id="idCAF8F32A82464A2AB2B44EA26087C0B7" section-type="subsequent-section"><enum>2141.</enum><header>Establishment of an
influenza vaccine target and stockpile</header>
<subsection commented="no" display-inline="no-display-inline" id="idE87A4EA0DBE64DF697587568FC670753"><enum>(a)</enum><header>Annual
target</header><text display-inline="yes-display-inline">The Secretary, in
consultation with the Advisory Committee on Immunization Practices to the
Centers for Disease Control and Prevention (referred to in this subtitle as the
<quote>Advisory Committee</quote>), shall determine an annual production target
for influenza vaccine, based on the recommendations of the Advisory Committee.
Based on such target, the Secretary, acting through the Centers for Disease
Control and Prevention, shall coordinate with the private market to encourage
the production of such vaccine in amounts that will meet the annual
target.</text>
</subsection><subsection commented="no" display-inline="no-display-inline" id="id408926091E934DACB56AADB7C504D0F6"><enum>(b)</enum><header>Stockpile</header><text display-inline="yes-display-inline">Prior to the start of each annual influenza
season (as determined by the Secretary), the Secretary is authorized to
purchase and store from multiple manufacturers an amount not to exceed 10
percent of the total amount of influenza vaccine, including one or more active
vaccine antigen ingredients in bulk or filled form, that is designated for
production by the Advisory Committee for placement in the strategic national
stockpile under section 121 of the Public Health Security and Bioterrorism
Preparedness and Response Act of 2002 (referred to in this subtitle as the
<quote>strategic national stockpile</quote>). Such vaccine shall be held in
reserve to be used in the event of a vaccine shortage in a given influenza
season. The Secretary shall coordinate with the manufacturers involved to
ensure that reserving amounts of vaccine for the stockpile does not interfere
with the early season delivery or early season administration of vaccine to
high priority populations (as defined by the Advisory Committee on Immunization
Practices and the Centers for Disease Control and Prevention) (referred to in
this subtitle as <quote>high priority populations</quote>).</text>
</subsection></section><section id="id6847234603214DE09ACAD145A3E5C6F5"><enum>2142.</enum><header>Vaccine
buyback program</header>
<subsection id="id18F07DE86E054FDCBAABED4FF532764C"><enum>(a)</enum><header>In
general</header><text>The Secretary shall establish an influenza vaccine
buyback protocol under which the Secretary may enter into buyback contracts
with manufacturers of influenza vaccine to purchase such manufacturers' excess
stocks of influenza vaccine so long as such vaccine has been manufactured in
accordance with the recommendations of the Advisory Committee for the
production of seasonal influenza vaccine.</text>
</subsection><subsection id="id546D824C91554CD191FB86B25C5E4CC5"><enum>(b)</enum><header>Manufacturers</header><text>The
Secretary shall have the discretion to award buyback contracts under subsection
(a) to several influenza vaccine manufacturers in a manner consistent with the
goal of providing stability in the influenza vaccine market, as long as the
Federal Government purchases not more than 50 percent of the excess influenza
vaccine stock of any single manufacturer at market price.</text>
</subsection><subsection id="id0AC90C4DE70946E7B735C4BFE40F9BD5"><enum>(c)</enum><header>Cooperation
with manufacturers, distributors, and wholesalers</header><text>As a condition
of participation in the buyback program under this section, the Director of the
Centers for Disease Control and Prevention shall work in cooperation with
influenza vaccine manufacturers and wholesalers and distributors within the
chain of custody from factory to health care institution or health care
providers to share pertinent information that will allow for the tracking of
influenza vaccine, maximize the delivery and availability of influenza vaccines
to high priority populations, and ensure that influenza vaccine is delivered on
an equitable basis, particularly in times of vaccine shortages.</text>
</subsection><subsection id="ID4fc6c280279e4a5993efbe877ecf5844"><enum>(d)</enum><header>Confidentiality</header><text>The
information submitted to the Centers for Disease Control and Prevention or its
contractors, if any, under subsections (c) and (d) shall remain confidential in
accordance with the exception from the public disclosure of trade secrets,
commercial or financial information, and information obtained from an
individual that is privileged and confidential, as provided for in section
552(b)(4) of title 5, United States Code, and subject to the penalties and
exceptions under sections 1832 and 1833 of title 18, United States Code,
relating to the protection and theft of trade secrets, and subject to privacy
protections that are consistent with the regulations promulgated under section
264(c) of the Health Insurance Portability and Accountability Act of 1996. None
of such information provided by a manufacturer, wholesaler, or distributor
shall be disclosed without its consent to another manufacturer, wholesaler, or
distributor, or shall be used in any manner to give a manufacturer, wholesaler,
or distributor a proprietary advantage over its competitors.</text>
</subsection><subsection id="id63A2BB63E23D492BBEA0BFF84FF5B111"><enum>(e)</enum><header>Ability To
negotiate</header><text>The Secretary shall have the ability to negotiate, on a
case-by-case basis, the submission of information under subsection (c), as long
as the information provided will achieve the goals of tracking of the influenza
vaccine, maximizing the delivery and availability of influenza vaccines to high
priority populations, and ensuring that influenza vaccine is delivered on an
equitable geographical basis, particularly in times of vaccine
shortages.</text>
</subsection><subsection id="idC431BD34172546788F078753CD3B17D4"><enum>(f)</enum><header>Notice</header>
<paragraph id="IDca5fdf9ec706403a8349747013d5aaa1"><enum>(1)</enum><header>In
general</header><text>For purposes of maintaining and administering the supply
of vaccines described under subsection (a), the Secretary shall by contract
require that a manufacturer of a vaccine included in such supply provide not
less than 12 months notice to the Secretary of a purposeful discontinuance of
the manufacture of such vaccine by the manufacture of the vaccine.</text>
</paragraph><paragraph id="ID319c7285706843979680975687160c66"><enum>(2)</enum><header>Reduction of
period of notice</header><text>The notification period required under paragraph
(1) shall not apply in a case in which vaccine production is interrupted
because of unforeseen manufacturing concerns.</text>
</paragraph></subsection><subsection id="idE3576CEB51D44C88874651ABA9F9146C"><enum>(g)</enum><header>Use of vaccine
post buyback</header><text>Following the buyback of vaccine under this section,
the Secretary shall direct that any vaccine purchased in such buyback be used
for the following activities:</text>
<paragraph id="idD522162B1D684D79B90EA3DF7AF76B55"><enum>(1)</enum><text>Use in
late-season mass vaccination exercises conducted in coordination with Federal,
State or local agencies engaged in emergency preparedness and bioterrorism
preparedness activities. Such exercises should be carried out in partnership
with voluntary organizations working to improve emergency preparedness and
bioterrorism preparedness.</text>
</paragraph><paragraph id="id2C679687EF394AADB5D671FB39C7E656"><enum>(2)</enum><text>Promoting and
carrying out late-season vaccination through the Indian Health Service, the
Public Health Service, the Department of Veterans Affairs, or through other
federally funded health care providers, such as community health centers and
rural health clinics.</text>
</paragraph><paragraph id="id0BF5AB47B4FC4C8997B8CB4A3C202832"><enum>(3)</enum><text>Other activities
approved by the Secretary.</text>
</paragraph></subsection></section><section id="idFB1644E0E0CE4A52A061558B1305E3AD"><enum>2143.</enum><header>Critical
supply purchase program</header>
<subsection id="ID8a2e5648d8de4a3f9c5a259c8ff854fb"><enum>(a)</enum><header>In
general</header><text>The Secretary shall increase the amount of antiviral
medications, N–95 respirator masks, and other protections and treatments, as
determined necessary by the Secretary as they become available, to treat and
prevent pandemic influenza, in the strategic national stockpile. In increasing
such amounts, the Secretary shall consult with the Director of the Centers for
Disease Control and Prevention and the Assistant Secretary for Preparedness and
Response, to determine the amounts that are necessary to provide adequate
protection to not less than the number of individual who respond to an
influenza epidemic.</text>
</subsection><subsection id="ID2df0920a8f544db9957a6f34325243ab"><enum>(b)</enum><header>Pediatric
programs</header><text>The Secretary is encouraged to consult with all relevant
Federal agencies and the private sector to develop and approve N–95 respirators
and other protections and treatments, as determined necessary by the Secretary,
to treat and prevent pandemic influenza, and shall ensure that such products
are represented in adequate amounts in the strategic national stockpile to
provide adequate protection to pediatric populations in the United
States.</text>
</subsection></section><section id="id34E3AAB313F8425FAADE803C57CDDFF4"><enum>2144.</enum><header>Authorization
of appropriations</header>
<subsection id="ID8fb97baf962a42b7aa8c02264c56a186"><enum></enum><text>There are
authorized to be appropriated such sums as may be necessary to carry out this
subtitle in each of fiscal years 2008 through
2012.</text>
</subsection></section></subtitle><after-quoted-block>.</after-quoted-block></quoted-block>
</section><enum>II</enum><header>Food and Drug
Administration assistance to manufacturers</header>
<section id="id41F1731FDD2C40338F20AB423F9CC1D2"><enum>201.</enum><header>Amendment to
the Food, Drug, and Cosmetic Act</header><text display-inline="no-display-inline">Chapter IX of the Federal Food, Drug, and
Cosmetic Act (21 U.S.C. 391 et seq.) is amended by adding at the end the
following:</text>
<quoted-block display-inline="no-display-inline" id="idE32A5A1CF8BE410FA166E185F8230A4B" style="OLC">
<section id="id0168B83C80AD4C23A5B781B252E13587"><enum>909.</enum><header>Provisions
related to the emergency acquisition of vaccines</header>
<subsection id="id26E06B0C8F894189B8E7B41124E13165"><enum>(a)</enum><header>In
general</header>
<paragraph id="id812167A2F6D24217858020FFD5BBCE27"><enum>(1)</enum><header>Increased
communication</header><text>The Food and Drug Administration shall carry out
activities to increase communication between the agency and the scientific
community regarding vaccine development and regulation, including participation
in conferences on the science related to infectious diseases, influenza,
biologic manufacturing, and other issues as determined appropriate by the
Director of the Center for Biologics Evaluation and Research.</text>
</paragraph><paragraph id="id26D716BF79474D3DB8426B175142376D"><enum>(2)</enum><header>Regulatory
roadmap</header><text>The Commissioner, in consultation with the Director of
the Centers for Disease Control and Prevention, the Secretary, and other
agencies or participants as determined appropriate by the Secretary, shall
develop a regulatory roadmap to address the following issues surrounding
emergency use authorization of influenza vaccine, as determined by the
Secretary during a public health emergency involving an actual or imminent
outbreak of naturally occurring or engineered seasonal influenza:</text>
<subparagraph id="id744F85BDA6AD41CA8A0F55BC2E9135F2"><enum>(A)</enum><text>Policies for the
emergency use authorization of influenza vaccine that is produced and sold in
other countries so that such vaccine may be imported into the United States by
the United States Government during a vaccine shortage.</text>
</subparagraph><subparagraph id="idE903156B97EC4846B32270A89853CEFE"><enum>(B)</enum><text>Policies for the
facilitation of the distribution of any such vaccine imported into the United
States during a vaccine shortage, including the interstate transportation,
allocation and equitable distribution of vaccine among high priority
populations (as defined by the Advisory Committee on Immunization Practices and
the Centers for Disease Control and Prevention) during an emergency use
situation.</text>
</subparagraph><subparagraph id="ID9988992a1b08470090e09bfe1865d0f9"><enum>(C)</enum><text>Policies for the
communication and coordination of a response to an emergency use authorization
with State and local health departments, including guidelines for notification
of such entities in such situations.</text>
</subparagraph><subparagraph id="id611D643538304CBB8060C0026A599705"><enum>(D)</enum><text>Policies for the
emergency use authorization of vaccines that are in clinical development in
both the United States and other countries, including clarification of IND
protocols for such vaccines, particularly those using new vaccine development
technologies.</text>
</subparagraph></paragraph><paragraph id="id73500132DF55441FA1F7C244B5D10268"><enum>(3)</enum><header>Consultation</header><text>In
developing the roadmap under paragraph (2), the Commissioner shall solicit
input from private and nonprofit stakeholders, including State and local health
officials, and such input shall include recommendations for developing
emergency use authorization guidelines that maintain the scientific and
regulatory standards of the Food and Drug Administration.</text>
</paragraph><paragraph id="id14F6438DF2F441CC9074996DD223AE6C"><enum>(4)</enum><header>Standing
orders</header>
<subparagraph id="idA63902F786BC48B6A4EBE27F1DEE2FC8"><enum>(A)</enum><header>Development</header><text>The
Secretary shall direct the Centers for Disease Control and Prevention, in
conjunction with State and local health departments and representatives of
State medical boards and nursing examiners, to develop and publish a model
standing order that will, at a minimum, address the need for standing orders to
administer influenza vaccine in hospitals, community health centers, nursing
homes, and other assisted living facilities, and by home health care providers.
The Centers for Disease Control and Prevention is encouraged to expand such a
model standing order to take into account—</text>
<clause id="id409E656C10E543E4ABBF1D85A2CEAB4B"><enum>(i)</enum><text>the
administration of other Medicare covered vaccines; and</text>
</clause><clause id="id4D8F3E2C41464D65BCD61309E54C5E3E"><enum>(ii)</enum><text>the delivery of
influenza vaccine to patients in children's hospitals or other institutions
serving the long-term care needs of a pediatric population, including those in
a non-clinical setting.</text>
</clause></subparagraph><subparagraph id="IDddec9e3fe40e47e9935f3e0659bb289c"><enum>(B)</enum><header>Implementation</header><text>Not
less than 1 year after the publication of the standing order under paragraph
(A), States shall be required to implement such standing order in order to be
eligible to receive grants under this Act.</text>
</subparagraph><subparagraph id="IDee77555c9868459e941c9fcaf230af6b"><enum>(C)</enum><header>Rule of
construction</header><text>Nothing in this paragraph shall be construed as
precluding the application of State laws, so long as such laws do not restrict
the implementation of this requirements of the
<short-title>Influenza Vaccine Security Act of
2007</short-title> (and the amendments made by such Act).</text>
</subparagraph></paragraph></subsection><subsection id="id72E9F27145D94ADB860A2A99B6DFA033"><enum>(b)</enum><header>Authorization
of appropriations</header><text>There are authorized to be appropriated to
carry out this section, $5,000,000 for fiscal year 2008, and such sums as may
be necessary for each of fiscal years 2009 through 2012, to be made available
to the Food and Drug Administration to provide the technical assistance and
take advantage of the training opportunities as designated in this
section.</text>
</subsection></section><after-quoted-block>.</after-quoted-block></quoted-block>
</section><enum>III</enum><header>Vaccine
education, outreach, and coordination</header>
<section commented="no" id="idF442B8053BC440FB8FE8B64F54BF5F37"><enum>301.</enum><header>Authority of
the National Center for Immunization and Respiratory Diseases for coordination,
education, outreach, and communication across HHS</header><text display-inline="no-display-inline">Section 2102 of the Public Health Service
Act (42 U.S.C. 300aa–2) is amended—</text>
<paragraph commented="no" id="idA40516C6C8A1477B8AE173D8B5125B7D"><enum>(1)</enum><text display-inline="yes-display-inline">in subsection (a), by adding at the end the
following:</text>
<quoted-block display-inline="no-display-inline" id="idC726A4772088441689F1FC53E9859B67" style="OLC">
<paragraph commented="no" id="IDc81102eb946540b4bcfc4248a0ed3d7b"><enum>(10)</enum><header>Coordination
of support</header><text>The Director of the Center, in consultation with the
Director of the National Institute for Allergy and Infectious Disease,
shall—</text>
<subparagraph commented="no" id="IDf54600eb1e054292b8190c5a59fb8179"><enum>(A)</enum><text>coordinate
efforts in regard to all influenza vaccine education, outreach, surveillance,
and research activities within the Department in support of the goal of—</text>
<clause commented="no" id="ID3423481ea3f346d292fdab77e7e3ee66"><enum>(i)</enum><text>increasing
overall influenza vaccination rates in the United States, particularly those of
high priority populations (as defined by the Advisory Committee on Immunization
Practices and the Centers for Disease Control and Prevention) and health care
providers;</text>
</clause><clause commented="no" id="idD1407C2E83E241BF9DF8EF738CA97900"><enum>(ii)</enum><text>increasing
vaccination rates among medically underserved populations with low vaccination
rates; and</text>
</clause><clause commented="no" id="idED322DFCD755449E82723B6A99711EC8"><enum>(iii)</enum><text>any other
vaccine promotion activities as directed by the Secretary;</text>
</clause></subparagraph><subparagraph commented="no" id="ID648808d6c6b842b798476dab9723108a"><enum>(B)</enum><text>coordinate
educational efforts under this paragraph with the National Vaccine Program
Office, State and local health departments, the National Institutes of Health,
and all other relevant Federal and other entities as designated by the
Director; and</text>
</subparagraph><subparagraph commented="no" id="IDe644350c4c7e40b0857faefcfd24a70b"><enum>(C)</enum><text>provide an annual
report to Congress on the progress being made toward the goals described in
subparagraph (A).</text>
</subparagraph></paragraph><after-quoted-block>;
and</after-quoted-block></quoted-block>
</paragraph><paragraph commented="no" id="id93F24442D9F6402ABD69CF322F2495F8"><enum>(2)</enum><text>by adding at the
end the following:</text>
<quoted-block display-inline="no-display-inline" id="id6262D34F894C453DB8AFE5EDC7F08DFD" style="OLC">
<subsection commented="no" id="ID5c41a24d3ecb4261821fcdc6c69bb3fa"><enum>(c)</enum><header>Appropriations
for coordination of influenza vaccine outreach activities</header><text>There
is authorized to be appropriated to carry out activities under subsection
(a)(10), $2,000,000 for each of fiscal years 2008 through
2012.</text>
</subsection><after-quoted-block>.</after-quoted-block></quoted-block>
</paragraph></section><enum>IV</enum><header>Increased
influenza vaccine and outbreak surveillance activities</header>
<section id="idA8015556D63F4B69BD38EEEBED7E955C"><enum>401.</enum><header>Tracking
network and demonstration grants</header><text display-inline="no-display-inline">Title III of the Public Health Service Act
is amended by inserting after section 319B (42 U.S.C. 247d–2) the
following:</text>
<quoted-block display-inline="no-display-inline" id="idB7DD6271B9154B17A93C784612025ABB" style="OLC">
<section id="id164E78CB48B74C768FA5AE814B78DCCF"><enum>319B–1.</enum><header>Tracking
network and demonstration grants</header>
<subsection id="idB65107F820C740B6803D0C5AC23C1C80"><enum>(a)</enum><header>Tracking
system</header>
<paragraph id="id9A171AB3AAD54599B021F37C147F3658"><enum>(1)</enum><header>Establishment</header><text display-inline="yes-display-inline">Not later than 2 years after the date of
enactment of this section, the Director of the Centers for Disease Control and
Prevention, in conjunction with State and local public health officials and
health provider and nonprofit organizations, shall establish an electronic
tracking system through which the Director and such officials can determine the
amount of influenza vaccine within a 24-hour window that is available for
distribution to patients, as well as the need for such vaccine on a
county-by-county basis, and the progress of vaccine delivery and distribution
efforts at the State and local level.</text>
</paragraph><paragraph id="id746BDA5E1BD74AB2B8818E05A497B3EE"><enum>(2)</enum><header>Estimates</header><text>The
tracking system established under paragraph (1) shall collect estimates of the
size of high priority populations (as defined by the Advisory Committee on
Immunization Practices and the Centers for Disease Control and Prevention)
(referred to in this section as <quote>high priority populations</quote>) in
each county in the United States, so as to better determine where influenza
vaccine resources may need to be directed in the case of an emergency.</text>
</paragraph><paragraph id="IDc0e258dca1a64eb2b9ac4b54b057d4b3"><enum>(3)</enum><header>Provision of
information</header><text>To be eligible to participate in buyback programs the
vaccine manufacturer shall provide information to the tracking system as the
Director of the Centers for Disease Control and Prevention determines
appropriate in accordance with subtitle 3 of title XXI.</text>
</paragraph><paragraph id="IDb9ba81383aca46dcaf7ce8de25c6dbf5"><enum>(4)</enum><header>Confidentiality</header><text>The
information submitted to the Secretary (or a contractors, if any) under this
section or under any other section of this Act related to vaccine distribution
information shall remain confidential in accordance with the exception from the
public disclosure of trade secrets, commercial or financial information, and
information obtained from an individual that is privileged and confidential, as
provided for in section 552(b)(4) of title 5, United States Code, and subject
to the penalties and exceptions under sections 1832 and 1833 of title 18,
United States Code, relating to the protection and theft of trade secrets, and
subject to privacy protections that are consistent with the regulations
promulgated under section 264(c) of the Health Insurance Portability and
Accountability Act of 1996. None of such information provided by a
manufacturer, wholesaler, or distributor shall be disclosed without its consent
to another manufacturer, wholesaler, or distributor, or shall be used in any
manner to give a manufacturer, wholesaler, or distributor a proprietary
advantage.</text>
</paragraph><paragraph id="ID5c26e1c27aa84ef5913a6d56656ec0e5"><enum>(5)</enum><header>Guidelines</header><text>The
Secretary, in order to maintain the confidentiality of relevant information and
ensure that none of the information contained in the systems involved may be
used to provide proprietary advantage within the vaccine market, while allowing
State, local, and tribal health officials access to such information to
maximize the delivery and availability of vaccines to high priority
populations, during times of influenza pandemics, vaccine shortages, and supply
disruptions, in consultation with manufacturers, distributors, wholesalers and
State, local, and tribal health departments, shall develop guidelines
permitting the Department of Health and Human Services to carry out paragraphs
(1) and (2) and (3).</text>
</paragraph></subsection><subsection id="id8AF6A4F1CEC04B69B4098BEDE33BB2E3"><enum>(b)</enum><header>Expansion of
current systems and activities</header>
<paragraph id="id2C8D762E227C4FD5A97FDAD1A27F6FCB"><enum>(1)</enum><header>Surveillance
system</header><text>Not later than 4 years after the date of enactment of this
section, the Director of the Centers for Disease Control and Prevention shall
upgrade and enhance the influenza surveillance system of the Centers for
Disease Control and Prevention to report influenza data from State and local
health departments into the tracking system established under subsection
(a)(1).</text>
</paragraph><paragraph id="idE33E9E1BF65D4FA086FBAAF22677EA1A"><enum>(2)</enum><header>Educational
materials</header><text>The tracking system shall contain information to assist
users in accessing influenza education, outreach, and communications tools,
such as those developed and financed under the
<short-title>Influenza Vaccine Security Act of
2007</short-title> (and the amendments made by such Act).</text>
</paragraph></subsection><subsection id="id6A0D13E1AD3A44DB9B28BE534459705B"><enum>(c)</enum><header>Demonstration
grants</header>
<paragraph id="id30FFD436FDCD46DCBC91FAEFE16A21B6"><enum>(1)</enum><header>In
general</header><text>The Director of the Centers for Disease Control and
Prevention shall award demonstration grants to State and local health
departments to enable such departments to enter into contract with hospitals,
community health centers, long-term care facilities, physicians’ offices, and
health care facilities operated or funded by such departments to assist such
department and entities in upgrading their information technology,
infrastructure, and workforce in a manner that will allow such departments and
entities to improve their ability to report and track influenza vaccine
dissemination.</text>
</paragraph><paragraph commented="no" display-inline="no-display-inline" id="id9C6AAB03E133453DA2CA77BED8C55F54"><enum>(2)</enum><header>Priority</header><text>In
awarding grants under paragraph (1), priority shall be given to departments and
entities that serve high priority populations in medically underserved
areas.</text>
</paragraph></subsection><subsection id="id9A579091C2E948C1A5A762D7099CF8B1"><enum>(d)</enum><header>Authorization
of appropriations</header><text>There are authorized to be appropriated—</text>
<paragraph id="idBF055F95AE184680870C4B3C7DD9EA92"><enum>(1)</enum><text>to carry out
subsection (a), $100,000,000 for each of fiscal years 2008 through 2012, of
which $500,000 for each fiscal year shall be made available to implement
subsection (b)(3); and</text>
</paragraph><paragraph id="id1B10CF0876964EF78F57A8F95FA6D717"><enum>(2)</enum><text>to carry out
subsection (c), $100,000,000 for each of fiscal years 2008 through
2012.</text>
</paragraph></subsection></section><after-quoted-block>.</after-quoted-block></quoted-block>
</section><enum>V</enum><header>Flu
vaccine outreach and education</header>
<section id="id597B5D7C1B294FE09638649247EBEE76"><enum>501.</enum><header>Educational
efforts and grants</header><text display-inline="no-display-inline">Title III
of the Public Health Service Act is amended by inserting after section 319B–1
(as added by section 401) the following:</text>
<quoted-block display-inline="no-display-inline" id="id63E029E1E3524FE8AD1A19393E75B57B" style="OLC">
<section id="idD56D08E9024D4AD0AF2602862F3035A6"><enum>319B–2.</enum><header>Immunization
educational efforts and grants</header>
<subsection id="idF835E02828244B1799D021205B9CA6DB"><enum>(a)</enum><header>In
general</header><text>The Director of the Centers for Disease Control and
Prevention, in conjunction with State and local health departments, shall
revise and expand the influenza-related educational materials to the Centers
for Disease Control and Prevention, and facilitate the use of such materials by
health care providers and patients. The Director is authorized to coordinate
such educational efforts with nonprofit provider and patient advocacy
groups.</text>
</subsection><subsection id="id50E7F520AE094DAEB1E2BE3B0CD96C5F"><enum>(b)</enum><header>Influenza
vaccine education and outreach</header>
<paragraph id="idEC4E929E7EF94F109AB9B9C0FC63ACD1"><enum>(1)</enum><header>In
general</header><text display-inline="yes-display-inline">In order to achieve
an optimal balance in the influenza vaccine market, and to ensure that the
recommendations of the Advisory Committee on Immunization Practices to the
Centers for Disease Control and Prevention for vaccine administration are
carried out to the maximum extent possible, the Director of the Centers for
Disease Control and Prevention, in conjunction with State and local health
departments, shall carry out influenza immunization education and outreach
activities that target physicians and other health care providers, health
insurance providers, health care institutions and patients, particularly those
in high priority populations (as defined by the Advisory Committee on
Immunization Practices and the Centers for Disease Control and Prevention)
(referred to in this section as <quote>high priority
populations</quote>).</text>
</paragraph><paragraph id="idDD985BAC7A604B73B3F27888CE700AEF"><enum>(2)</enum><header>Types of
activities</header><text display-inline="yes-display-inline">The education and
outreach activities under paragraph (1) shall include—</text>
<subparagraph id="ID7ba609ac3f3c40f1984c0a5643bd117a"><enum>(A)</enum><text>activities to
encourage voluntary participation in influenza vaccination programs, with the
goal of increasing overall influenza vaccination rates in the United States,
achieving full influenza vaccination of all high priority populations, and full
use of each season’s influenza vaccine supply and late season
vaccination;</text>
</subparagraph><subparagraph id="IDe06b048573a74bab827d1828273afd99"><enum>(B)</enum><text>the provision of
information on influenza prevention, including to medically underserved
communities with low vaccination rates;</text>
</subparagraph><subparagraph id="id270E11D6B3904944AEFB23F773A1380A"><enum>(C)</enum><text>activities to
increase the number of healthcare providers who receive influenza vaccines each
year; and</text>
</subparagraph><subparagraph id="ID9f40dc47f6ed4d3894fc652f542e3697"><enum>(D)</enum><text>other influenza
educational efforts determined appropriate by the Director.</text>
</subparagraph></paragraph></subsection><subsection id="id7F817508B3FB4CC883E2B2C0FBA12510"><enum>(c)</enum><header>Grants</header><text>The
Director of the Centers for Disease Control and Prevention may award grants to
State and local health departments to carry out activities to encourage
individuals, particularly those from high priority populations, to seek out
influenza vaccinations.</text>
</subsection><subsection id="IDe6eef2b6f0d64c0db2af8a245025bb64"><enum>(d)</enum><header>Collaboration</header><text>State
and local health departments that receive grants under subsection (b) are
encouraged to collaborate on projects with physicians and other health care
providers, health insurance providers, health care institutions, and groups
representing high priority populations.</text>
</subsection><subsection id="id4503D3954C0949718E733627AF7C8563"><enum>(e)</enum><header>Authorization
of appropriations</header><text>In addition to any amounts otherwise available
through the Secretary for influenza outreach and education, there is authorized
to be appropriated to carry out this section, $10,000,000 for each of fiscal
years 2008 through
2012.</text>
</subsection></section><after-quoted-block>.</after-quoted-block></quoted-block>
</section>